Frankfurt - Delayed Quote EUR
Hofseth BioCare ASA (HBQ.F)
0.1820
+0.0060
+(3.41%)
At close: May 16 at 9:39:12 PM GMT+2
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Jon Olav Odegard | Chief Executive Officer | 176.99k | -- | -- |
Dr. Bomi Framroze | Chief Scientific Officer | 778.65k | -- | 1961 |
Mr. James Berger | Chief Commercial Officer | 173.73k | -- | -- |
Ms. Angelika Florvaag | Chief Quality Officer | 119.48k | -- | -- |
Mr. Magnus Havnen | Head of Supply Chain | -- | -- | -- |
Mr. Tom James | Head of Manufacturing | -- | -- | -- |
Hofseth BioCare ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 72
Description
Hofseth BioCare ASA engages in the production of health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Europe, Japan, Asia, and the United States. The company's products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for weight management, and metabolism; CalGo, a calcium collagen complex for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was founded in 2000 and is headquartered in Ålesund, Norway.
Corporate Governance
Hofseth BioCare ASA’s ISS Governance QualityScore as of May 1, 2025 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 10; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available